Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04175834 (ClinicalTrials.gov)	February 5, 2020	22/11/2019	Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab	Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions	Multiple Sclerosis;Infusion Reaction	Drug: antihistamine	Providence Health & Services	Genentech, Inc.	Active, not recruiting	18 Years	70 Years	All	52	Phase 3	United States
2	EUCTR2013-001055-12-IT (EUCTR)	28/05/2015	03/06/2013	Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß.	Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß. - FLU-LIGHT	Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneß, suffering from flu-like syndrome (FLS). MedDRA version: 16.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Cetirizina Mylan Generics Product Name: Cetirizina Mylan Generics INN or Proposed INN: Cetirizina Other descriptive name: CETIRIZINE HYDROCHLORIDE	Biogen Idec Italia S.r.l.	NULL	Not Recruiting			Female: yes Male: yes			Italy
3	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovir;Drug: esomeprazole;Drug: ibuprofen;Drug: paracetamol	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain
4	NCT02865018 (ClinicalTrials.gov)	April 2014	9/8/2016	Neuromyelitis Optica (NMO) & Cetirizine	An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica	Neuromyelitis Optica	Drug: cetirizine	Icahn School of Medicine at Mount Sinai	Guthy Jackson Foundation	Completed	18 Years	85 Years	Both	16	Phase 1/Phase 2	United States
5	NCT00240032 (ClinicalTrials.gov)	October 2004	13/10/2005	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.	A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.	Multiple Sclerosis	Drug: glatiramer acetate injection with oral cetirizine hydrochloride;Drug: glatiramer acetate with placebo	Teva Pharmaceutical Industries	NULL	Completed	18 Years	N/A	Both	80	Phase 4	United States

先頭へ